Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
Merck
AstraZeneca
Baxter

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,886,035

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,886,035 protect, and when does it expire?

Patent 5,886,035 protects ZIOPTAN and is included in one NDA.

This patent has twenty patent family members in thirteen countries.

Summary for Patent: 5,886,035
Title: Difluoroprostaglandin derivatives and their use
Abstract:A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: ##STR1## wherein A is a vinylene group or the like, R.sup.1 is an aryloxyalkyl group or the like, R.sup.2 and R.sup.3 are hydrogen atoms or the like, and Z is OR.sup.4 (wherein OR.sup.4 is a hydrogen atom or an alkyl group) or the like.
Inventor(s): Shirasawa; Eiichi (Ikoma, JP), Kageyama; Masaaki (Ikoma, JP), Nakajima; Tadashi (Ikoma, JP), Nakano; Takashi (Yokohama, JP), Mori; Nobuaki (Yokohama, JP), Sasakura; Hideshi (Yokohama, JP), Matsumura; Yasushi (Yokohama, JP), Morizawa; Yoshitomi (Yokohama, JP)
Assignee: Asahi Glass Company Ltd. (Tokyo, JP) Santen Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:08/993,017
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,886,035
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 5,886,035

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Oak Pharms Inc ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 AT RX Yes Yes   Start Trial   Start Trial Y Y REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,886,035

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan8-348614Dec 26, 1996
Japan9-074054Mar 26, 1997
Japan9-172477Jun 27, 1997

International Family Members for US Patent 5,886,035

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 225770   Start Trial
Canada 2225761   Start Trial
China 1108289   Start Trial
China 1187486   Start Trial
Germany 122008000050   Start Trial
Germany 69716226   Start Trial
Denmark 0850926   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Boehringer Ingelheim
AstraZeneca
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.